MANNITOL
Molecular Excipient
| Mwt. | LogP | HBD | HBA | PSA | RB | CSP3 |
|---|---|---|---|---|---|---|
| 182.0 | -3.6 | 6 | 6 | 121.0 | 5 | 1.0 |
- CAS
- 69658
- UNII
- 3OWL53L36A
- SYNONYMS
-
- ZINC ID(s)
- Availability
- Present in 76 ZINC catalogs
Known Active Genes
There has not been any activity reported at 10μM or less for this excipient (per ChEBML)
Clinical Trials
This compound has been an intervention in the following clincial trials (per clinicaltrials.gov).
| Code | Date | Title | Phase | Status |
|---|---|---|---|---|
| NCT00359697 | Comparison of Two Different Medications Used to Treat Elevated Intracranial Pressure | Phase 1 | Not Yet Recruiting | |
| NCT01954290 | 2015-08-01 | Study of Stroke Related Edema Treatments | Phase 2 | Not Yet Recruiting |
| NCT02386449 | 2015-02-01 | A Study Comparing Picoprep With Mannitol and Bisacodyl for Colon Cleansing in Preparation for Colonoscopy | Phase 4 | Recruiting |
| NCT02306473 | 2015-01-01 | The Leaky Lung Test | Phase 0 | Not Yet Recruiting |
| NCT02134353 | 2014-10-01 | A Safety and Efficacy Trial of Inhaled Mannitol in Adult Cystic Fibrosis Subjects | Phase 3 | Recruiting |
| NCT02244372 | 2014-09-01 | Efficacy and Safety of Cordyceps Sinensis Mycelium Culture Extract(Paecilomyces Hepiali, CBG-CS-2) on Promotion of Immunity | Phase 2/Phase 3 | Recruiting |
| NCT02196142 | 2014-08-01 | Acute Effects of Cortisol on Alcohol Craving in Alcohol Dependence | Phase 3 | Not Yet Recruiting |
| NCT02037815 | 2014-01-01 | Correlation of Measured and Calculated Serum Osmolality During Hyperosmolar Drugs Infusion in Patients After Craniotomy | Phase 4 | Completed |
| NCT01883531 | 2013-06-01 | Crossover Trial Determining the Efficacy of Dry Powder Mannitol to Improve Lung Function in Subjects Aged 6-17 Years | Phase 2 | Recruiting |
| NCT01843088 | 2013-05-01 | Trial of Mannitol Cream for Pain Relief After a Long Run | Phase 1 | Completed |
| NCT02091180 | 2013-01-01 | Mannitol Improves Cerebral Oxygen Saturation | Phase 4 | Completed |
| NCT01748838 | 2012-12-01 | Phase 1 Study Assessing the Safety and Tolerability of CTX-4430 | Phase 1 | Completed |
| NCT01718964 | 2012-11-01 | Acute Effects of Cortisol on Heroin Craving in Opioid Dependence (Ghost-Basel) | Phase 2 | Completed |
| NCT01745081 | 2012-09-01 | Comparison of 20% Mannitol and 3% Hypertonic Saline for Cerebral Relaxation During Elective Supratentorial Craniotomies | Phase 4 | Recruiting |
| NCT01682408 | 2012-09-01 | Assess Pharmacokinetics of Fostamatinib in Fed and Fasted State in Combination With Ranitidine to Assess Bioavailability | Phase 1 | Completed |
| NCT01605357 | 2012-07-01 | Hypernatremia for the Prevention and Treatment of Cerebral Edema in Traumatic Brain Injury | Phase 1/Phase 2 | Not Yet Recruiting |
| NCT01645085 | 2012-07-01 | A Study to Assess the Bioequivalence of R406 in Healthy Volunteers When Given 100mg and 150 mg of Fostamatinib | Phase 1 | Completed |
| NCT01520207 | 2012-05-01 | Mannitol - Potential Role in Hemodialysis Initiation for Reduction of Intra-dialytic Hypotension | Phase 2 | Recruiting |
| NCT01606787 | 2012-05-01 | Mannitol Use During Partial Nephrectomy Prior to Renal Ischemia and Impact on Renal Function Outcomes | Phase 3 | Recruiting |
| NCT01485315 | 2011-11-01 | Transfusion-requirements in Septic Shock Trial | Phase 3 | Completed |
| NCT01642745 | 2011-11-01 | Mannitol (Aridol) and Methacholine (Provocholine) Responsiveness | Phase 4 | Completed |
| NCT01449123 | 2011-09-01 | Mannitol Challenge Test in Adult Asthma Patients With Fixed Dose Combinations | Phase 4 | Completed |
| NCT01142505 | 2010-11-01 | Wheeze and Intermittent Treatment | Phase 3 | Completed |
| NCT00810940 | 2010-10-01 | Controlled Trial of ABELADRUG200 in Closed, Severe Head Injury | Phase 1/Phase 2 | Recruiting |
| NCT01111682 | 2010-04-01 | Hypertonic Saline vs. Mannitol for Elevated Intercranial Pressure | Phase 3 | Terminated |
| NCT00669331 | 2009-11-01 | Inhaled Mannitol as a Mucoactive Therapy for Bronchiectasis | Phase 3 | Completed |
| NCT00189007 | 2009-10-01 | Antenatal Allopurinol During Fetal Hypoxia | Phase 3 | Active, Not Recruiting |
| NCT00973284 | 2009-09-01 | Norwalk Vaccine Study | Phase 1/Phase 2 | Completed |
| NCT01309178 | 2009-05-01 | Anti-inflammatory Pulmonal Therapy of Cystic Fibrosis (CF) Patients With Amitriptyline and Placebo | Phase 2 | Recruiting |
| NCT01076491 | 2009-01-01 | High Dose Inhaled Mannitol Study | Phase 1/Phase 2 | Completed |
| NCT00792714 | 2008-12-01 | Pharmacokinetics of Inhaled Mannitol in Cystic Fibrosis Patients | Phase 1 | Completed |
| NCT00795587 | 2008-10-01 | Comparison of 2 Doses of Mannitol on Post Traumatic Intracranial Hypertension and Cerebral Monitoring | Phase 4 | Terminated |
| NCT00630812 | 2008-09-01 | Long Term Administration of Inhaled Mannitol in Cystic Fibrosis | Phase 3 | Completed |
| NCT00730977 | 2008-08-01 | A Pilot Study to Investigate Administration of Mannitol Via a Novel Dry Powder Inhaler Device | Phase 1/Phase 2 | Completed |
| NCT01028339 | 2008-07-01 | Mannitol vs HS to Treat ICHT After Severe TBI : Comparison on PtiO2 and Microdialysis Values | Phase 3 | Terminated |
| NCT00569088 | 2007-11-01 | "Study of the Pathogenesis and Molecular Mechanism of ""YURE"" in Internal Intractable Diseases" | Phase 2 | Recruiting |
| NCT01233492 | 2007-10-01 | Boron Phenylalanine With or Without Mannitol in Treating Patients With Glioblastoma Multiforme | Phase 1 | Terminated |
| NCT00446680 | 2007-03-01 | Long Term Administration of Inhaled Dry Powder Mannitol In Cystic Fibrosis - A Safety and Efficacy Study | Phase 3 | Completed |
| NCT00446667 | 2006-10-01 | A Pilot Safety Study of Inhaled Dry Powder Mannitol in Acute Exacerbations of COPD | Phase 1/Phase 2 | Completed |
| NCT00446771 | 2006-10-01 | A Pharmacokinetic and Bioavailability Study of Mannitol for Inhalation Using Normal Subjects | Phase 1 | Completed |
| NCT00677664 | 2006-07-01 | Effects of Copaxone in the Retinal Function in Diabetic Patients After Panphotocoagulation | Phase 4 | Active, Not Recruiting |
| NCT00277537 | 2006-03-01 | Safety and Efficacy of Bronchitol in Bronchiectasis | Phase 3 | Completed |
| NCT00117208 | 2005-11-01 | Comparison of Inhaled Mannitol and rhDNase in Children With Cystic Fibrosis | Phase 2 | Completed |
| NCT00251056 | 2005-10-01 | Mannitol Dose Response Study in Cystic Fibrosis | Phase 2 | Completed |
| NCT00125229 | 2005-08-01 | Cerebral Hemodynamic Effects of Hypertonic Solutions in Severely Head-Injured Patients | Phase 4 | Terminated |
| NCT00117182 | 2005-07-01 | Aridol Challenge as a Tool to Predict Treatment Response to Inhaled Corticosteroids in COPD | Phase 2 | Completed |
| NCT00238173 | 2004-12-01 | Acetylcysteine, Mannitol, Combination Chemotherapy, and Sodium Thiosulfate in Treating Children With Malignant Brain Tumors | Phase 1 | Suspended |
| NCT00113854 | 2004-10-01 | Mannitol as Adjunct Therapy for Childhood Cerebral Malaria | Phase 3 | Active, Not Recruiting |
| NCT00455130 | 2004-03-01 | A Phase 2 Study to Determine the Safety and Efficacy of Inhaled Dry Powder Mannitol in Cystic Fibrosis | Phase 2 | Completed |
| NCT00319345 | 2003-11-01 | Sodium-Lactate and Traumatic Brain Injury | Phase 2/Phase 3 | Terminated |
| NCT00426192 | 2003-10-01 | Effects of Hemofiltration and Mannitol Treatment on Cardiopulmonary-Bypass Induced Immunosuppression | Phase 4 | Active, Not Recruiting |
| NCT00390624 | 2003-07-01 | Prevention Of Nephrotoxicity Following Bone Marrow Transplantation Using Urodilatin and Mannitol | Phase 2 | Completed |
| NCT00447018 | 2002-10-01 | Mannitol Versus Hypertonic Saline Solution in the Treatment of Elevated Intracranial Pressure | Phase 4 | Completed |
(Browse) Purchasable Analogs in ZINC
Functions of Mannitol
| Nutr - Nutrient |
Regulatory Status of Mannitol
| Gras - Generally recognized as safe. |
Dosages
| Route | Formulation | Per Unit Dose |
|---|---|---|
| Buccal | Tablet | 97.69MG |
| Buccal/sublingual | Tablet | 52.5MG |
| Im - Iv | Injection | 2.5% |
| Im - Iv | Powder, For Injection Solution | 15%W/V |
| Im - Iv - Sc | Injection | |
| Im - Sc | Injection | |
| Im - Sc | Powder, For Injection Solution | 2% |
| Intramuscular | Injectable | 5% |
| Intramuscular | Injection | 10.66% |
| Intramuscular | Injection | 9.45% |
| Intramuscular | Injection, Microspheres | 13.49% |
| Intramuscular | Powder, For Injection Solution | 11.93% |
| Intramuscular | Powder, For Injection Solution, Lyophilized | 8.5% |
| Intramuscular | Powder, For Injection Solution, Lyophilized, With Additives | 3.6% |
| Intramuscular | Powder, For Injection Suspension | 4.5% |
| Intramuscular | Powder, For Injection Suspension, Lyophilized | 5.19% |
| Intravenous | Infusion | 17% |
| Intravenous | Injectable | 45% |
| Intravenous | Injection | 4% |
| Intravenous | Injection, Suspension | 12.5% |
| Intravenous | Liquid, Concentrate, Injection | 6.13% |
| Intravenous | Powder | 45% |
| Intravenous | Powder, For Injection Solution | 34% |
| Intravenous | Powder, For Injection Solution, Lyophilized | 4%W/V |
| Intravenous | Powder, For Injection Solution, Lyophilized, With Additives | 3.94% |
| Intravenous | Solution | 4.15% |
| Intravenous | Solution, Injection | 74.8% |
| Intravenous | Solution, Liposome, Injection | 10% |
| Iv(Infusion) | Concentrate | 22% |
| Iv(Infusion) | Infusion | 3.85% |
| Iv(Infusion) | Injectable | 4.95% |
| Iv(Infusion) | Injection | 4.7%W/V |
| Iv(Infusion) | Powder, For Injection Solution | 1.5%W/V |
| Iv(Infusion) | Powder, For Injection Solution, Lyophilized, With Additives | 7.5% |
| Iv(Infusion) | Solution, Concentrate | 4.4% |
| Iv(Infusion) | Solution, Injection | 20.67% |
| Nasal | Solution, Spray | 4.15% |
| Ophthalmic | Gel | 5% |
| Ophthalmic | Powder, For Solution | 5.6% |
| Ophthalmic | Solution | 23% |
| Ophthalmic | Solution, Drops | 4.6% |
| Ophthalmic | Solution, Gel Forming, Extended Release | 4.35% |
| Ophthalmic | Suspension | 2.4% |
| Ophthalmic | Suspension, Drops | 4% |
| Oral | Capsule | 297.2MG |
| Oral | Capsule (Immed./comp. Release), Hard Gelatin | 264.8MG |
| Oral | Capsule, Coated Pellets | 1.75MG |
| Oral | Capsule, Delayed Action | 13.44MG |
| Oral | Capsule, Delayed Action, Enteric Coated | |
| Oral | Capsule, Enteric Coated Pellets | 236MG |
| Oral | Capsule, Extended Release | 6.42MG |
| Oral | Capsule, Hard Gelatin | 92MG |
| Oral | Capsule, Sustained Action | 56.1MG |
| Oral | Dispersible Tablet | 8.6MG |
| Oral | Granule | 484.2MG |
| Oral | Granule, Effervescent | |
| Oral | Granule, For Oral Suspension | 193.2MG |
| Oral | Granule, For Suspension | 500MG |
| Oral | Powder | 19.3% |
| Oral | Powder | 1.1GM |
| Oral | Powder, For Oral Solution | 5.78%W/V |
| Oral | Powder, For Oral Suspension | 5.29% |
| Oral | Powder, For Reconstitution | 5.87% |
| Oral | Powder, For Solution | |
| Oral | Powder, For Suspension | 4% |
| Oral | Solution, Injection | 2.94% |
| Oral | Suspension | 10% |
| Oral | Suspension, Sustained Action | 2.46GM |
| Oral | Tablet | 681.65MG |
| Oral | Tablet (Immed./comp. Release), Film Coated | 181.5MG |
| Oral | Tablet (Immed./comp. Release), Film Coated | 32.58MG |
| Oral | Tablet (Immed./comp. Release), Uncoated, Chewable | 630MG |
| Oral | Tablet, Coated | 177.7MG |
| Oral | Tablet, Controlled Release | |
| Oral | Tablet, Delayed Action | 106.12MG |
| Oral | Tablet, Delayed Action, Enteric Coated | 77.9MG |
| Oral | Tablet, Delayed Release | 83MG |
| Oral | Tablet, Dispersible | 104MG |
| Oral | Tablet, Extended Release | 384.75MG |
| Oral | Tablet, Film Coated | 241.21MG |
| Oral | Tablet, For Suspension | 270MG |
| Oral | Tablet, Orally Disintegrating | 606.72MG |
| Oral | Tablet, Orally Disintegrating | 174.78MG |
| Oral | Tablet, Orally Disintegrating | 174.76MG |
| Oral | Tablet, Orally Disintegrating, Delayed Release | 221MG |
| Oral | Tablet, Sustained Action | 392.2MG |
| Oral | Tablet, Sustained Action, Film Coated | 274.97MG |
| Oral | Tablet, Uncoated, Lozenge | 187.6MG |
| Oral | Troche | 1035.18MG |
| Oral | Wafer | 500MG |
| Parenteral | Powder For Injection | 1GM |
| Parenteral | Powder, For Injection Solution | 20% |
| Respiratory (Inhalation) | Powder, For Inhalation | 0.05% |
| Subcutaneous | Injectable | 10% |
| Subcutaneous | Injection | 4.5% |
| Subcutaneous | Powder, For Injection Solution | 9% |
| Subcutaneous | Powder, For Injection Solution, Lyophilized | 22.05% |
| Subcutaneous | Powder, For Injection Solution, Lyophilized, With Additives | 4% |
| Subcutaneous | Powder, For Injection Suspension, Lyophilized | 10% |
| Subcutaneous | Solution | 1.59% |
| Subcutaneous | Solution, Injection | 4.95% |
| Subcutaneous | Suspension, Injection | 1.21% |
| Sublingual | Tablet | 164.92MG |
| Sublingual | Tablet (Immed./comp. Release), Uncoated, Buccal | 157.48MG |
| Submucosal | Solution, Injection | 2.94% |
| Topical | Solution | 2.39%W/V |
| Topical | Solution, Drops | 1.6%W/V |
| Topical | Suspension | 0.3% |
| Transdermal | Patch, Electrically Controlled | 342.35MG |
| Transmucosal | Tablet | 180.19MG |